Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase II-trial to Investigate Safety and Efficacy of an Adjuvant Therapy With Gemcitabine and Erbitux® in Patients With R0 or R1 Resected Pancreatic Cancer

NCT00395252 is registered in ClinicalTrials.gov with Carmen Schade-Brittinger as lead sponsor.

NCT NCT00395252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00395252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase II-trial to Investigate Safety and Efficacy of an Adjuvant Therapy With Gemcitabine and Erbitux® in Patients With R0 or R1 Resected Pancreatic Cancer
Lead sponsor
Carmen Schade-Brittinger
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
January 31, 2012
Enrollment
76 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma